BRST5:Volunteer Assignments and Opportunities: Difference between revisions
No edit summary |
No edit summary |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 42: | Line 42: | ||
|[[BRST5:Usual ductal hyperplasia|Usual ductal hyperplasia]] | |[[BRST5:Usual ductal hyperplasia|Usual ductal hyperplasia]] | ||
|Disease | |Disease | ||
|Ritika Pathak | |||
|2/25/2026 | |||
| | | | ||
|PENDING | |||
| | | | ||
| | |Katherine Geiersbach | ||
| | | | ||
| | | | ||
| Line 114: | Line 114: | ||
| | | | ||
|- | |- | ||
|[[BRST5:Lactating adenoma|Lactating adenoma]]||Disease|| | |[[BRST5:Lactating adenoma|Lactating adenoma]]||Disease||Joanna George | ||
| | |3/28/2026 | ||
| | | | ||
|PENDING | |||
| | | | ||
|Katherine Geiersbach | |||
| | | | ||
| | | | ||
| Line 179: | Line 179: | ||
| | | | ||
|- | |- | ||
|[[BRST5:Papillary ductal carcinoma in situ|Papillary ductal carcinoma in situ]]||Disease|| | |[[BRST5:Papillary ductal carcinoma in situ|Papillary ductal carcinoma in situ]]||Disease||Sresi Singh (trainee), Katherine Geiersbach | ||
| | |2/26/2026 | ||
| | | | ||
|PENDING | |||
| | | | ||
|Katherine Geiersbach | |||
| | | | ||
| | | | ||
| Line 253: | Line 253: | ||
| | | | ||
|- | |- | ||
|[[BRST5:Invasive breast carcinoma of no special type|Invasive breast carcinoma of no special type]]||Disease|| | |[[BRST5:Invasive breast carcinoma of no special type|Invasive breast carcinoma of no special type]]||Disease||Braa Elwaleed Mohamed Ahmed (trainee) +Katherine to find mentor | ||
|2/20/2026 | |||
| | | | ||
|PENDING | |||
| | | | ||
|Katherine Geirsbach | |||
| | | | ||
| | | | ||
|- | |||
|[[BRST5:Microinvasive carcinoma|Microinvasive carcinoma]]||Disease|| | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| Line 280: | Line 280: | ||
| | | | ||
|- | |- | ||
|[[BRST5:Tubular carcinoma|Tubular carcinoma]]||Disease|| | |[[BRST5:Tubular carcinoma|Tubular carcinoma]]||Disease||Sree Vishmaya | ||
| | |3/20/2026 | ||
| | | | ||
| | | | ||
| | | | ||
|Katherine Geiersbach | |||
| | | | ||
| | | | ||
| Line 469: | Line 469: | ||
| | | | ||
|- | |- | ||
|[[BRST5:Fibroadenoma|Fibroadenoma]]|| || | |[[BRST5:Fibroadenoma|Fibroadenoma]]|| Disease||Aamer Ahmed Fairoze (trainee), Katherine Geiersbach as mentor | ||
| | |2/20/2026 | ||
| | | | ||
|PENDING | |||
| | | | ||
|Katherine Geiersbach | |||
| | | | ||
| | | | ||
| Line 529: | Line 529: | ||
| | | | ||
|- | |- | ||
|[[BRST5:Paget disease of the breast|Paget disease of the breast]]||Disease|| | |[[BRST5:Paget disease of the breast|Paget disease of the breast]]||Disease||Aamer Ahmed Fairoze (trainee), Katherine Geiersbach as mentor | ||
| | |2/20/2026 | ||
| | | | ||
|PENDING | |||
| | | | ||
|Katherine Geiersbach | |||
| | | | ||
| | | | ||